Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications
International Journal of Tuberculosis and Lung Disease, Volume 20, No. 4, Year 2016
Notification
URL copied to clipboard!
Description
BACKGROUND: Management of extensively drug-resistant tuberculosis (XDR-TB) and pre-XDR-TB is challenging, as effective drugs are lacking. Group 5 antituberculosis drugs have an unclear role in the treatment of drug-resistant TB, and in children the efficacy, safety and effects of long-Term use are not well described. We present clinical outcomes and adverse effects of a cohort of children with XDR-TB or pre-XDR-TB treated with Group 5 drugs in Tajikistan. METHODS : We conducted a retrospective analysis of eight children treated with one or more of the Group 5 drugs available under the Tajikistan National TB Programme-linezolid, amoxicillin-clavulanate, clofazimine and clarithromycin-given in combination with first-and second-line drugs. Time to sputum culture conversion, clinical outcomes and adverse effects were evaluated. RESULT S : Two children were cured, one completed treatment, four achieved favourable interim outcomes and one died. Adverse effects attributable to linezolid that required drug cessation occurred in one child; adverse effects of the other Group 5 drugs were insignificant or absent, requiring no regimen changes. CONCLUS ION: Group 5 drugs can contribute to effective regimens in children with XDR and pre-XDR-TB. With proper monitoring and aggressive management of adverse effects, their safety profile might be acceptable, even in long-Term use. © 2016 The Union.
Authors & Co-Authors
Du Cros, Philipp A.
United Kingdom, London
Msf
Seddon, James Alexander
United Kingdom, London
Msf
United Kingdom, London
Imperial College London
Achar, Jay
United Kingdom, London
Msf
Statistics
Citations: 11
Authors: 3
Affiliations: 3
Identifiers
Doi:
10.5588/ijtld.15.0666
ISSN:
10273719
Research Areas
Infectious Diseases
Maternal And Child Health
Study Design
Cohort Study